image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Our latest issue will be released in 9 days, don't miss out!

4Imprint - 18% order book growth blows out forecasts

September 2023

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • FOUR
  • Price:
  • 4925p
The shares spiked £8 to above £52 at one point and are now £12 above my main write-up price in last September’s issue. The catalyst was another upgrade to full year guidance with turnover expected to be “slightly above US$1.3 billion” and pretax profit materially above current consensus of forecasts and not less than US$125m.” This was driven by strong order growth (+18%), improving gross margin (benefiting from input cost deflation and tactical pricing), strong returns on marketing  and expansion of operational capacity. As we go to press, it has also announced interims with operating profit up 45% to US$63.8m (op margin +1.25% to 10%) and eps up 48% to 176.2 cents. Liberum has upgraded full year pretax profit and eps by 1 ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Related Articles

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

author